Combined Amneal adds bevacizumab and Gemini

Amneal has struck a licensing deal with Mabxience for exclusive US rights to biosimilar Avastin (bevacizumab) and has acquired branded player and hybrid 505(b)(2) specialist Gemini Laboratories for US$117 million, at the same time as announcing the completion of its merger with Impax, creating the “fifth-largest US generics player”.